Loading clinical trials...

Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA | Clinical Trials | Clareo Health

RECRUITINGNA

Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA

NCT05354765•Institut Curie

View on ClinicalTrials.gov

Summary

The study will evaluate the detection of tumor-antigen specific immune cells in cancer patients in whom the role of the immune system is suspected.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patient aged 18 or over,
•2. Patient presenting an invasive tumor pathology (proven or suspected). The location and / or stage of which are defined for each cohort through an amendment to the protocol,
•3. Patient treated with immune-modulators or other treatments likely to modify immunological parameters,
•4. Suspicion of immune mediated response or toxicities (assessed by the immunologists),
•5. Peripheral venous capital usable and compatible with the realization of 2 venous accesses for lymphapheresis and absence of cardiovascular problem (heart failure, arrhythmia ...), per investigator assessement,
•6. Total circulating lymphocytes\> 1000 / mm3,
•7. Availability of DNA and RNA from the tumor,
•8. Information to the patient and signature of informed consent or his legal representative,
•9. Affiliated with a social security scheme or such a scheme.

Exclusion Criteria

•1. Inability to undergo study follow-up for geographical, social or psychological reasons,
•2. Infection with HIV or hepatitis B or C viruses,
•3. Patients on high dose corticosteroid treatment (\> 1 mg / kg continuously),
•4. Any concomitant serious illness that may interfere with participation in the study or significantly affect the results of the study (pulmonary, heart or liver disease),
•5. Contraindication to performing lymphapheresis (coagulation disorder, cardiovascular problems, venous access, hypocalcemia, psychological inability to undergo extracorporeal circulation, cachexia, etc.),
•6. Pregnant patient or of childbearing age without effective contraception,
•7. Persons deprived of their liberty, under guardianship or legal protection.

Locations (2)

Institut Curie

Paris, France

Institut Curie

Saint-Cloud, France

Key Dates

Start Date

August 31, 2022

Primary Completion Date

September 3, 2026

Completion Date

September 3, 2026

Last Updated

January 24, 2025

Enrollment

300

ESTIMATED participants

Conditions

CancerImmune System or Toxicities Suspected

Interventions

blood sample

OTHER

blood sample

OTHER

Contacts

Cyrine EZZILI, PhD

CONTACT

0033147111657 cyrine.ezzili@curie.fr

Fouzia AZZOUZ

CONTACT

fouzia.azzouz@curie.fr

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

RECRUITINGPHASE2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA

Inclusion Criteria

Exclusion Criteria

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)